Yes, will be interesting to watch.
Similar in CVac really only through the target, MUC-1.
Stimuvax uses a liposomal delivery, CVac is personalised with autologous dendritic cells.
Stimuvax isn't the one to watch from Oncothyreon, though. ONT-10 looks better in most respects except pipeline.
watch this space, page-3
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 120143 | 36.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.0¢ | 37025 | 1 |
View Market Depth
| Last trade - 10.00am 12/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
Day chart unavailable